Rekvina Laboratories Ltd

Rekvina Laboratories Limited informed the BSE Limited that it has received a certificate from Purva Sharegistry India Pvt. Ltd., the company's Registrar and Share Transfer Agent, for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Rekvina Laboratories Limited announced the appointment of Mr. Subrata Samanta as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 7, 2026, according to a regulatory filing with the BSE Limited.

Rekvina Laboratories Limited informed the Bombay Stock Exchange that the trading window for securities of the company will be closed from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, in accordance with the company’s code of fair disclosure and SEBI regulations.

Rekvina Laboratories Limited informed the BSE that its Board of Directors approved a change of registered office within the city, effective September 23, 2026, to 3rd floor 5 Laxmi Society, B/h Baroda Heart Institute, Near Haribhakti Colony, Old padra Road, Vadodara – 390007, and noted the resignation of Mr. Amit Shah as Managing Director, effective September 11, 2026, due to personal reasons and commitments.

Rekvina Laboratories Limited informed the BSE that Mr. Deepak Khandelwal has resigned from the position of Company Secretary and Compliance Officer, effective September 2, 2026, due to personal reasons.

Rekvina Laboratories Limited is acquiring 100% of Radiant Parenterals Limited through a share swap, issuing 46,27,750 new equity shares at Rs 10 per share, valued at a total consideration of Rs 4,62,77,500. Simultaneously, Rekvina is conducting a preferential allotment of 4,60,000 new equity shares to Amitkumar Arunkumar Rao and Amitkumar Arunkumar Rao HUF for Rs 46,00,000 in cash, priced at Rs 10 per share including a Rs 5 premium. The acquisition, deemed an arm's length transaction, is expected to complete within 15 days of regulatory approvals, including in-principle exchange approval and a special resolution. The moves are intended to expand Rekvina’s market presence and create shareholder value, although they will result in dilution of existing shareholders’ ownership.

Rekvina Laboratories Limited will hold a board meeting on August 13, 2026, to consider and approve the un-audited standalone financial results under Indian Accounting Standards (Ind AS) for the quarter ended June 30, 2026, and other agendas, according to a regulatory filing with the BSE Limited. The company has also closed the trading window for its equity shares for designated persons from July 1, 2026, until 48 hours after the financial results are made public.

Net Loss of Rekvina Labs reported to Rs 0.06 crore in the quarter ended March 2026 as against net loss of Rs 0.04 crore during the previous quarter ended March 2025. Sales reported to Rs 0.72 crore in the quarter ended March 2026. There were no Sales reported during the previous quarter ended March 2025. For the full year,net loss reported to Rs 0.25 crore in the year ended March 2026 as against net loss of Rs 0.14 crore during the previous year ended March 2025. Sales reported to Rs 1.27 crore in the year ended March 2026. There were no Sales reported during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales0.720 0 1.270 0 OPM %-8.330 --19.690 - PBDT-0.06-0.04 -50 -0.25-0.14 -79 PBT-0.06-0.04 -50 -0.25-0.14 -79 NP-0.06-0.04 -50 -0.25-0.14 -79 Powered by Capital Market - Live

Rekvina Labs will hold a meeting of the Board of Directors of the Company on 21 May 2026.

Rekvina Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 April 2026.Powered by Capital Market - Live